MedCity News November 3, 2024
As multi-billion investment continues to pour into the R&D of future obesity medications, the need for evidence generation of health benefits beyond short-term weight loss will be critical to the decision-making of healthcare providers and payers.
Nearly seven years after the FDA approved Novo Nordisk’s Ozempic for diabetes treatment, this medication and other GLP-1 receptor agonists have proven very effective in promoting weight loss. For the millions struggling with obesity, they offer a way to reduce appetite, manage blood sugar levels, lose weight, and decrease the risk of the comorbidities associated with having a higher body mass.
The World Obesity Federation has warned that by 2035 approximately 4.4 billion people globally will be classified as obese. This would lead to...
Today's Sponsors
Today's Sponsor